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books, and those outside the field who need to look up terms related to medicine.
While the scientific terms are not described at such a basic level to suggest a lay
audience, there is a wide range of medically related issues referenced. This volume
certainly has its own unique niche among reference books, but it is not, and cannot




NOVEL ANTIPSYCHOTIC DRUGS. Edited by Herbert Y. Meltzer. New York, Raven
Press, 1992. 267 pp. $90.00.
The field of schizophrenia research is rapidly changing. The advent of clozapine
has led to the exploration of new pharmacotherapeutic strategies based on mecha-
nisms other than dopamine-2 receptor blockade, the hallmark oftypical neuroleptic
treatment. As a result, investigators have explored many new approaches to antipsy-
chotic treatment based on dopamine-1 receptor blockade, serotonin-2 receptor
antagonism, serotonin-3 receptor blockade, enhancement of excitatory amino acid
neurotransmission, and other novel approaches. As a result, people working within
thefieldofschizophrenia andfamilymembersofindividualsafflictedwithschizophre-
nia frequently seek reference material that provides a snapshot progress report of
novel pharmacotherapeutic approaches to schizophrenia. NovelAntipsychotic Drugs,
edited by Herbert Meltzer, a leader in the psychopharmacology of schizophrenia,
fulfills at least a part of this need by providing very brief introductions to treatment
strategies based on a spectrum ofneurobiological mechanisms.
Some of the 23 chapters in this book represent work in progress, bearing the
strengths and weaknesses of this type of communication. Clinical investigators are
hungry for information about drugs such as risperidone, amperozide, odansetron,
remoxipride, and raclopride. Thisvolume provides briefinformative updates, but no
definitive findings, regarding the use of these agents in treating schizophrenic
patients. Chapters by investigators such as John Waddington, Philip Seeman, Carol
Tamminga, and their colleagues manage to bridge approaches to the pathophysiol-
ogy of schizophrenia and novel pharmacotherapeutic findings in short but informa-
tive chapters. Some ofthis material is unavailable in any other published source. An
otherwise interesting chapterbyJohn Olney, a leader in the field ofexcitatory amino
acid neurotoxicity, draws parallels between neurotoxic and psychotomimetic effects
of NMDA antagonists too closely. Olney suggests that anticholinergic agents would
be antipsychotic, based on his data indicating that they protect against PCP-induced
toxicity in the cingulate cortex. He ignores pre-clinical behavioral data and clinical
studies suggesting that anticholinergic agents exacerbate and cholinergic agents
alleviate the behavioral effects ofPCP.
The key to this book is its timeliness. Priced at $90.00, this slim volume is unlikely
to find its way into the personal library of many clinicians. At this price, this book
would need to contain classicpapers tobe useful in the long run. Itssnapshot reviews
and introductions are likely to be out ofdate in a fewyears. Important contributions
to the field ofschizophrenia that emerge from its preliminary research presentations
will eventually appear in the peer-reviewed literature. Advances that are blind alleys
ultimately will be forgotten. In the long run, volumes such as these often gather dust540 BOOK REVIEWS
on the back shelves of medical school libraries. During a critical period of time,
however, there is an urgent need for the information contained in this book. I, and
others interested in getting the latest update of a rapidly changing field, might do
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Both William James and Sigmund Freud believed in their time that the neural
basis ofemotion and memory is a most compelling but elusive area ofstudy. Despite
the great advances made in the neurosciences in the last decade, the study of
psychobiology is still an unsettled frontier. A wealth of new techniques have,
however, finally opened this fundamental area of research to experimental analysis.
John Aggleton, of the University of Durham, has assembled a formidable group of
clinical and laboratory investigators to present the latest and most excitingfindings in
the field of psychobiology in The Amygdala: Neurobiological Aspects of Emotion,
Memory, andMentalDysfunction.
The amygdala complex, a mass of gray matter located in the medial part of the
temporal lobe, is a critical structure in the generation of emotion and memory.
Despite abundant evidence implicating the amygdala in affect and memory forma-
tion, stress responsivity, epilepsy, senile dementia, schizophrenia, pathologic aggres-
sion, and even stomach ulceration, it has been a decade since a book devoted to the
subject has been published. But it has been worth the wait. Dr. Aggleton's The
Amygdala is an authoritative and comprehensive volume, which is essential reading
for anyone, whether expert or newcomer, who is interested in emotion and memory.
The name of this subcortical structure (from the Latin for almond, a somewhat
obscure reference to this structure's anatomical appearance) may be less familiar
than its better studied cortical cousin, the hippocampus. Nevertheless, both brain
areas have been considered allied structures since the time ofPierre Paul Broca, who
included both in his le grand lobe limbique over a century ago (and indeed, modern
neuroanatomical techniques have revealed abundant connections between the amyg-
dala and the hippocampus). In 1952, Paul MacLean, then at Yale University,
reintroduced Broca's term "limbic" for those structures which form an annular ring
of tissue on the medial aspect of the cerebral hemispheres. MacLean elaborated on
the Papez theory of 1937 that these limbic structures are involved in the generation
of emotion. But how do the amygdala and other limbic structures give rise to
emotion? How is this function related to memory formation? In short, whatprecisely
does the amygdala do?
The short answer is that the function of the amygdala remains an enigma, though
clues abound. In 1939, Heinrich Kluver and Paul Bucy at the University of Chicago
described a strange and dramatic syndrome following bilateral temporal lobectomy
in rhesus monkeys. The classic Kluver-Bucy syndrome in primates includes tame-
ness, hyperorality, altered sexuality, extreme distractability. In addition, these ani-
mals show a bizarre inability to appreciate sensory information, a condition referred